Jump to main content
eTG Complete
Index
Search
Home
Cardiovascular
Venous thromboembolism
Venous thromboembolism (VTE) prophylaxis
Parenteral anticoagulants for VTE prophylaxis
Cardiovascular
Atherosclerotic cardiovascular disease risk estimation
Modifiable lifestyle risk factors for atherosclerotic cardiovascular disease
Lipid modification
Blood pressure reduction
Acute chest pain of possible cardiac origin
Acute coronary syndromes
Stable angina
Antithrombotic therapy after endovascular and cardiac interventions
Secondary prevention of atherosclerotic cardiovascular events
Peripheral artery disease
Pericarditis
Heart failure
Cardiac rehabilitation programs
Tachyarrhythmias
Bradyarrhythmias
Orthostatic hypotension
Pulmonary hypertension
Venous thromboembolism
Venous thromboembolism (VTE) prophylaxis
Overview of VTE prophylaxis
Risk factors for VTE
Approach to VTE prophylaxis
Parenteral anticoagulants for VTE prophylaxis
Low molecular weight heparin for VTE prophylaxis
Unfractionated heparin for VTE prophylaxis
Fondaparinux for VTE prophylaxis
Danaparoid for VTE prophylaxis
Direct-acting oral anticoagulants for VTE prophylaxis
Aspirin for VTE prophylaxis following total hip or knee replacement
Mechanical VTE prophylaxis
VTE prophylaxis for nonsurgical patients
VTE prophylaxis for surgical patients
VTE prophylaxis for lower-limb immobilisation
VTE prophylaxis for long-distance travel
VTE prophylaxis during pregnancy and the postpartum period
VTE prophylaxis for patients with active cancer
References
Venous thromboembolism (VTE) treatment
Periprocedural management of patients with cardiovascular disease
Principles of anticoagulant therapy
Parenteral anticoagulants for VTE prophylaxis
Low molecular weight heparin for VTE prophylaxis
Unfractionated heparin for VTE prophylaxis
Fondaparinux for VTE prophylaxis
Danaparoid for VTE prophylaxis
